What Causes Hot Flashes? Supplements That Help and What to Know About HRT

What Actually Causes Hot Flashes

Hot flashes, clinically called vasomotor symptoms (VMS), are not simply "hormonal." They are a failure of the hypothalamus to regulate core body temperature accurately when estrogen levels drop. The hypothalamus contains a cluster of neurons in the infundibular nucleus (called KNDy neurons) that coordinate body temperature. Estrogen normally keeps these neurons quiet. When estrogen falls, KNDy neurons fire excessively, narrowing the thermoneutral zone, the range of body temperature the brain accepts before triggering a cooling response. Research published in the journal Menopause has confirmed that kisspeptin, neurokinin B, and dynorphin (the "KNDy" peptides) are the key mediators, which is why neurokinin B receptor antagonists like fezolinetant are now an FDA-approved non-hormonal option.

The Thermoneutral Zone: Why Your Body Overreacts

A woman with adequate estrogen has a thermoneutral zone of roughly 0.4°C. In perimenopause and post-menopause, that zone can shrink to nearly zero, meaning even tiny fluctuations in core temperature, a warm room, a glass of wine, mild stress, trigger a full heat-dissipation cascade: peripheral vasodilation, profuse sweating, a racing heart, and then chills as the body overshoots cooling.

Why Estrogen Decline Is the Central Driver

Estrogen does not fall in a straight line. During perimenopause, estradiol swings wildly before its long-term decline, which is why hot flashes can begin years before the final menstrual period. The Study of Women's Health Across the Nation (SWAN) followed over 3,300 women and found that VMS lasted a median of 7.4 years total, starting in perimenopause, and women who began flashing earlier (before the final period) had the longest overall duration.

Hot Flashes by Life Stage

Perimenopause (Typically Ages 44-52)

Estrogen fluctuates dramatically. Hot flashes often arrive erratically, linked to irregular cycles and estradiol spikes followed by crashes. Sleep disruption is frequently the first complaint. This is the stage where many women are still ovulating and can become pregnant, which matters for treatment decisions.

Post-Menopause

Defined as 12 or more consecutive months without a period. Estrogen is now persistently low. Flashes may intensify for 1-2 years after the final period before gradually decreasing for most (but not all) women. SWAN data show that African American women experience VMS for significantly longer durations than white or Asian women, on average 10.1 years versus 6.5 years, a disparity that remains poorly explained and under-studied.

Postpartum and Lactation

This is a genuinely under-recognized cause of hot flashes in younger women. Delivery is followed by an abrupt fall in estrogen and progesterone. Prolactin (elevated during breastfeeding) suppresses hypothalamic GnRH, further suppressing ovarian estrogen production. Studies in the journal Obstetrics and Gynecology confirm that hot flashes and night sweats are reported by a substantial proportion of postpartum women, peaking in the first weeks after delivery. These are physiological and typically resolve as ovarian function returns after weaning.

PCOS Across Reproductive Life

Women with polycystic ovary syndrome (PCOS) who use hormonal suppression therapies, or who enter menopause, may experience VMS. PCOS itself creates a state of irregular estrogen exposure and elevated androgens. During perimenopause, this picture becomes more complex: a 2023 analysis in Fertility and Sterility noted that women with PCOS tended to enter menopause later but did not have fewer vasomotor symptoms once they did.

Thyroid Disease and Hot Flashes

Hyperthyroidism can cause sweating, heat intolerance, palpitations, and flushing that mimic hot flashes almost exactly. Before attributing symptoms to menopause, a TSH measurement is warranted, particularly if weight loss, tremor, or anxiety is present. Hypothyroidism less commonly mimics VMS but can worsen fatigue and mood changes that accompany them. The American Thyroid Association guidelines recommend TSH as the initial test when thyroid disease is suspected. Postpartum thyroiditis, affecting roughly 5-10% of women in the year after delivery, can cause a hyperthyroid phase that produces heat symptoms easily confused with postpartum VMS.

What Triggers a Hot Flash

Triggers do not cause hot flashes; they lower the threshold for an episode in a nervous system already primed by estrogen deficiency. Common ones include:

• Alcohol, particularly red wine (acetaldehyde causes peripheral vasodilation)
• Caffeine in some women, though the evidence is not consistent
• Spicy food (capsaicin activates the same thermosensitive TRPV1 receptors involved in VMS)
• Hot beverages and warm environments
• Psychological stress (cortisol destabilizes hypothalamic thermoregulation)
• Smoking (associated with earlier menopause and worse VMS in multiple cohort studies)

Keeping a two-week symptom diary that logs time, duration, severity, and possible trigger can identify patterns worth modifying. It also gives your clinician a baseline to measure treatment response against.

Supplements for Hot Flashes: What the Evidence Shows

No supplement approaches the efficacy of hormone therapy. For women who cannot or do not want to use hormones, some options have meaningful trial data. The evidence base in women specifically is thin in many cases, partly because supplement trials historically enrolled small numbers of participants and rarely stratified by reproductive stage.

Phytoestrogens (Soy Isoflavones and S-Equol)

Phytoestrogens are plant compounds that bind weakly to estrogen receptors. The most studied are genistein and daidzein from soy. About 25-30% of Western women (and up to 50-60% of Asian women) produce S-equol, a gut-metabolite of daidzein with stronger estrogenic activity. Women who are "equol producers" appear to respond better to soy supplementation.

A 2021 meta-analysis in Menopause covering 35 randomized controlled trials found that soy isoflavones reduced hot flash frequency by approximately 26% versus placebo. Direct S-equol supplementation (10-40 mg/day) has shown reductions of roughly 50% in frequency in Japanese trials, though those populations had higher baseline equol-producer rates, limiting extrapolation to Western women.

Safety note: Phytoestrogens are generally considered safe for women with intact uteri and no hormone-receptor-positive breast cancer history, though long-term endometrial safety data remain limited. Women with a personal or family history of hormone-receptor-positive breast cancer should discuss phytoestrogens with their oncologist before starting.

Black Cohosh (Actaea racemosa)

Black cohosh is the most widely used botanical for VMS in the United States. Mechanistically, it does not appear to act on estrogen receptors; instead it may modulate serotonin and dopamine pathways. The Cochrane review on black cohosh for menopausal symptoms found inconsistent results across trials, with some showing modest benefit and others finding no difference from placebo.

Typical studied doses range from 20 to 40 mg of standardized extract (isopropanolic extract) twice daily. Duration of use beyond 6 months lacks long-term safety data. Rare cases of hepatotoxicity have been reported. Women with liver disease should avoid it.

Magnesium Glycinate

Magnesium plays a role in hypothalamic temperature regulation and GABA-ergic neurotransmission. A pilot trial published in the Journal of the Society of Integrative Oncology found that magnesium oxide 400-800 mg/day reduced hot flash frequency by about 41% in breast cancer survivors who could not use hormones. This was a small, unblinded trial. Larger confirmatory studies have not been published.

Magnesium is well-tolerated at doses below 350 mg elemental magnesium daily (the tolerable upper intake level for supplemental magnesium). Higher doses cause diarrhea in many women. Glycinate form has better gastrointestinal tolerability than oxide.

Cognitive Behavioral Therapy

This is not a supplement, but it belongs in any honest list because the evidence is better than for most botanicals. The MENOS 1 randomized trial found that a self-help CBT workbook significantly reduced VMS problem-rating (not frequency, but how much they bothered women) at 6 weeks compared to controls. VMS problem-rating is arguably more clinically meaningful than raw frequency. CBT likely works by reducing the cortical amplification of the flash experience rather than the underlying thermoregulatory event.

Supplements With Insufficient Evidence for Hot Flashes

Vitamin E (400 IU/day), evening primrose oil, and valerian have been studied in small trials. None has shown clinically meaningful benefit in adequately powered studies. They are not recommended as primary strategies.

Hormone Replacement Therapy (HRT) for Hot Flashes

Hormone therapy is the most effective treatment for vasomotor symptoms. Period. The 2023 Menopause Society position statement states that for healthy women under age 60 or within 10 years of menopause onset, the benefits of HRT for VMS outweigh the risks. That guidance applies to women without contraindications, including no personal history of hormone-receptor-positive breast cancer, no unexplained vaginal bleeding, no active thromboembolic disease, and no severe liver disease.

How HRT Reduces Hot Flashes

Estrogen replaces the hormonal signal that keeps KNDy neurons calm. Clinical trials consistently show a 75-90% reduction in hot flash frequency with adequate estrogen doses. The REPLENISH trial, which studied a combined 17-beta estradiol and progesterone oral capsule (Bijuva), demonstrated significant VMS reduction versus placebo in postmenopausal women, with a favorable bleeding profile.

Estrogen Routes of Administration: Why It Matters for Women

Transdermal estradiol (patches, gels, sprays) bypasses first-pass liver metabolism. This matters clinically because oral estrogens raise triglycerides, sex-hormone-binding globulin (SHBG), and C-reactive protein, all driven by hepatic first-pass effects. Transdermal estradiol does not raise VTE risk to the same degree as oral estrogen, according to a large observational study in the BMJ. For women with elevated cardiovascular risk, migraine with aura, or hypertriglyceridemia, transdermal is the preferred route.

Progestogen: Who Needs It and Which Type

Any woman with an intact uterus must take a progestogen alongside estrogen to protect the endometrial lining from unopposed-estrogen-driven hyperplasia and cancer. Options include:

• Micronized progesterone (Prometrium, compounded bioidentical): closest to endogenous progesterone; preferred for women with cardiovascular risk and those who prioritize sleep quality
• Medroxyprogesterone acetate (MPA): the progestogen used in the Women's Health Initiative; associated with increased breast cancer signal in the combined arm
• Levonorgestrel-releasing IUD: provides local endometrial protection with minimal systemic progestogen absorption; an excellent option for perimenopausal women who also need contraception

Women who have had a hysterectomy can take estrogen alone, which carries a more favorable risk profile.

Timing: The "Window of Opportunity"

Starting HRT within 10 years of the final menstrual period or before age 60 is associated with cardiovascular benefit or neutrality. Starting after age 60 or more than 10 years after menopause may carry greater cardiovascular and cognitive risk. The Kronos Early Estrogen Prevention Study (KEEPS) demonstrated that oral conjugated equine estrogen and transdermal estradiol, started within 36 months of menopause, were both associated with slowed progression of subclinical atherosclerosis compared to placebo, though neither reached statistical significance on carotid intima-media thickness.

Non-Hormonal Prescription Options

For women who cannot use estrogen, two FDA-approved non-hormonal options exist:

1. Fezolinetant (Veozah): A neurokinin 3 receptor antagonist that directly silences the KNDy neurons driving VMS. Approved by the FDA in May 2023. The SKYLIGHT 1 and 2 trials showed approximately 60% reduction in moderate-to-severe hot flash frequency at 12 weeks.
2. Paroxetine mesylate 7.5 mg (Brisdelle): An SSRI that modulates serotonin thermoregulatory pathways. Reduces frequency by roughly 33-67% versus placebo. Not the same as standard antidepressant doses of paroxetine.

SSRIs and SNRIs more broadly (venlafaxine 75 mg, escitalopram 10-20 mg) are used off-label with modest evidence. They are particularly relevant for women with concurrent depression or anxiety.

The WomanRx Hot Flash Treatment Decision Framework by Life Stage:

| Life Stage | First-Line Option | Key Considerations | |---|---|---| | Perimenopause, still cycling | Low-dose combined hormonal contraceptive OR transdermal estradiol + levonorgestrel IUD | Must provide contraception; hormonal contraceptive suppresses VMS and prevents pregnancy | | Post-menopause, under age 60, <10 years since last period | Transdermal estradiol + micronized progesterone (if uterus intact) | Lowest VTE risk; best evidence for cardioprotection window | | Post-menopause, over age 60 OR >10 years since last period | Fezolinetant OR SSRI/SNRI; discuss HRT risk-benefit with specialist | Timing hypothesis applies; individualize | | Postpartum/breastfeeding | No systemic estrogen; CBT, trigger avoidance, cooling strategies | Symptoms resolve with weaning; progestogen-only options may be used for contraception | | PCOS, perimenopausal | Treat underlying metabolic factors; transdermal estradiol + progestogen if eligible | Androgen excess may complicate symptom picture | | Cannot use hormones (breast cancer history, active clot) | Fezolinetant, venlafaxine 75 mg, CBT | Discuss oncologist clearance for phytoestrogens |

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Pregnancy: Systemic estrogen-containing HRT is contraindicated in pregnancy. Estrogen in pharmacologic doses has not been shown to be teratogenic in humans, but there is no indication for it during pregnancy, and it must not be started without ruling out pregnancy in perimenopausal women who are still ovulating. Perimenopausal women can and do become pregnant; the final menstrual period cannot be confirmed until 12 months have passed. ACOG guidance recommends that perimenopausal women continue contraception until confirmed post-menopause.

Lactation: Systemic estrogen is generally avoided during breastfeeding because it suppresses milk production. Progestogen-only methods (mini-pill, levonorgestrel IUD, depot medroxyprogesterone acetate) do not impair lactation and are the standard contraceptive choice postpartum. Fezolinetant has no lactation data; it should be avoided. Black cohosh and soy isoflavones also lack adequate lactation safety data.

Contraception requirement: Any woman in perimenopause using HRT for VMS who still has any possibility of ovulation must use reliable contraception. Low-dose combined hormonal contraceptives (20 mcg ethinyl estradiol formulations) both suppress VMS and provide contraception in early perimenopause.

Who This Is Right For (and Who Should Pause)

Strong candidates for HRT

• Women aged 45-60 with moderate-to-severe VMS affecting sleep, work, or relationships
• Women with surgical menopause (oophorectomy) at any age: estrogen loss is abrupt and cardiovascular and bone risks are higher; hormone therapy is particularly important in this group
• Women with genitourinary syndrome of menopause (GSM) alongside VMS
• Women whose VMS began during perimenopause and who are still under 60 at the time of assessment

Women who need individual risk-benefit discussion

• Women with BRCA1/2 mutations (evidence is nuanced and evolving)
• Women with a history of VTE (transdermal estrogen may be appropriate; avoid oral)
• Women with hypertriglyceridemia (transdermal only; oral estrogen raises triglycerides further)
• Women with migraine with aura (oral combined estrogen/progestogen raises stroke risk; transdermal estradiol is considered safer)

Women for whom HRT is generally contraindicated

• Active hormone-receptor-positive breast cancer (discuss fezolinetant or SSRIs with oncologist)
• Active or recent VTE or stroke without clear reversible cause
• Unexplained uterine bleeding (investigation must come first)
• Active liver disease with impaired hepatic function

When to See a Clinician

A hot flash diary showing more than 7 moderate-to-severe episodes per day, or any VMS severe enough to disrupt sleep consistently, warrants a clinical conversation rather than self-management alone. Rule out thyroid disease with a TSH if you have never had one checked. If you are under 45 and experiencing VMS, premature ovarian insufficiency (POI) is a possibility that requires FSH and estradiol testing, per ACOG guidelines on POI.

Women with POI have a higher risk of cardiovascular disease and osteoporosis from decades of estrogen deficiency. Hormone therapy in POI is not optional in the same way it is in natural menopause; it is considered replacement of a physiologically necessary hormone and is recommended at least until the average age of natural menopause (around 51).

The Menopause Society recommends that women receive individualized counseling about all available VMS options, incorporating personal health history, values, and symptom severity. A clinician dismissing severe VMS as "just menopause" without offering evidence-based treatment options is not providing adequate care.